Inclacumab

Pfizer's withdrawal of Oxbryta from global markets due to increased risk of deaths and complications has left the sickle cell disease community reeling. Despite recent setbacks, hope for SCD treatment lies in next-gen transplantation and gene therapy, with St. Jude developing its own gene therapy. Pfizer's inclacumab and osivelotor, Agios Pharmaceuticals' mitapivat, Novo Nordisk's etavopivat, and Fulcrum Therapeutics' pociredir are among investigational therapies in the SCD pipeline.

Pfizer is withdrawing Oxbryta, a sickle cell disease drug, due to safety concerns, leading to an imbalance of deaths and vaso-occlusive crises. The European Medicines Agency recommended suspending its clearance. Pfizer acquired Oxbryta through its purchase of Global Blood Therapeutics in 2022, with Oxbryta generating $92 million in revenue in Q2 2024. Pfizer continues to develop other sickle cell treatments, including inclacumab and osivelotor in Phase 3. Patients currently on Oxbryta should consult their doctors for alternatives.

Pfizer withdraws Oxbryta, its sickle cell disease treatment, from global markets due to increased risks of vaso-occlusive crises and fatal events. The decision follows recent FDA approvals of two gene therapies for SCD, Casgevy and Lyfgenia, which offer potential cures but come with high costs.